See the DrugPatentWatch profile for tigecycline

Yes, I can provide an example of a bacterial infection treated with tigecycline. Tigecycline is an antibiotic used to treat a variety of bacterial infections, including complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [1]. It is a broad-spectrum antibiotic, meaning it is effective against a wide range of bacteria [1].

One specific example of a bacterial infection treated with tigecycline is complicated intra-abdominal infections (cIAI) [2]. cIAI are infections that occur in the abdominal cavity, often as a result of perforations or abscesses in the gastrointestinal tract [2]. These infections can be serious and life-threatening, and require prompt treatment with antibiotics [2].

Tigecycline has been shown to be effective in treating cIAI caused by a variety of bacteria, including Escherichia coli, Klebsiella pneumoniae, and Bacteroides fragilis [2]. In clinical trials, tigecycline has been shown to be non-inferior to other antibiotics commonly used to treat cIAI [2].

It's important to note that the use of tigecycline should be based on the susceptibility of the bacteria causing the infection, and the drug should be used in accordance with the approved labeling [1]. Additionally, the use of tigecycline should be consistent with the current guidelines of the relevant authorities [1].

In summary, tigecycline is an antibiotic used to treat a variety of bacterial infections, including complicated intra-abdominal infections caused by bacteria such as Escherichia coli, Klebsiella pneumoniae, and Bacteroides fragilis.

Sources:
[1] Tigecycline [package insert]. Wyeth Pharmaceuticals, a subsidiary of Pfizer Inc. 2010. Available at: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s016lbl.pdf>.
[2] Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133-164. doi:10.1086/649771. Available at: <https://academic.oup.com/cid/article/50/2/133/3053809>.